MiNK Therapeutics, Inc.

The momentum for this stock is not very good. MiNK Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in MiNK Therapeutics, Inc..

News

MiNK Therapeutics, Inc. (NASDAQ:INKT) Sees Large Growth in Short Interest

Ticker Report MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) was the recipient of a large growth in short interest in August. As of August 15th, there was short interest totalling 64,300 shares, a growth...\n more…

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Globe Newswire NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...\n more…

MiNK Therapeutics (NASDAQ:INKT) Rating Reiterated by HC Wainwright

Zolmax HC Wainwright reissued their buy rating on shares of MiNK Therapeutics (NASDAQ:INKT - Free Report) in a report issued on Tuesday morning, Benzinga reports. The brokerage currently has a $9.00 target...\n more…

Equities Analysts Set Expectations for MiNK Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:INKT)

Zolmax MiNK Therapeutics, Inc. (NASDAQ:INKT - Free Report) - Research analysts at HC Wainwright raised their Q3 2024 EPS estimates for MiNK Therapeutics in a research note issued on Tuesday, August 13th...\n more…

Q3 2024 EPS Estimates for MiNK Therapeutics, Inc. Lifted by William Blair (NASDAQ:INKT)

Zolmax MiNK Therapeutics, Inc. (NASDAQ:INKT - Free Report) - Equities researchers at William Blair boosted their Q3 2024 earnings per share (EPS) estimates for MiNK Therapeutics in a research report...\n more…

MiNK Therapeutics files to sell 4.64M shares of common stock for holders

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…